Short answer
Absci Corp (ABSI) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $318,000 (down 46.4% year over year) with net income of −$33M.
Q2 2026 key financials · XBRL
- Revenue
- $318,000
- −46.4% YoY · +47.9% QoQ
- Net income
- −$33M
- −8.6% YoY · −12.2% QoQ
- Operating margin
- -10741.5%
- EPS (diluted)
- −$0.21
- +12.5% YoY · −10.5% QoQ
Source: XBRL data from the Absci Corp (ABSI) Q2 2026 10-Q on SEC EDGAR. USD.
Absci Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.3M, down 46% YoY from $0.6M
- Operating loss $34.2M vs $31.4M YoY; operating margin -11,402% vs -5,294%
- Best-performing program ABS-201; interim safety data favorable, half-life at least 65 days
- Cash, equivalents, and securities $201.1M; operating cash use $53.9M vs $38.7M YoY
- June offering raised $93.6M; Phase 2 endometriosis trial anticipated Q4 2026
Risk Factors
- No material-change statement; filing reiterates 10-K risks without identifying a newly added trigger
- Partner-license risk: no partner had licensed related intellectual property for clinical or commercial use as of August 11, 2026
- FDA compliance risk: staffing changes or shortages could delay IND reviews, regulations, guidance, or enforcement
- Clinical-development risk: ABS-201 Phase 1/2a trial continued MAD dosing while other programs remained research or preclinical
- Liquidity risk: $201.1 million in cash, equivalents, and marketable securities expected to fund at least 12 months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Absci Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.